Zacks Small Cap Comments on Edesa Biotech Q1 Earnings

Edesa Biotech, Inc. (NASDAQ:EDSA) – Equities researchers at Zacks Small Cap issued their Q1 2026 EPS estimates for Edesa Biotech in a research report issued on Monday, December 15th. Zacks Small Cap analyst D. Bautz anticipates that the company will post earnings per share of ($0.25) for the quarter. The consensus estimate for Edesa Biotech’s current full-year earnings is ($1.75) per share. Zacks Small Cap also issued estimates for Edesa Biotech’s Q2 2026 earnings at ($0.24) EPS, Q3 2026 earnings at ($0.23) EPS, Q4 2026 earnings at ($0.23) EPS, FY2026 earnings at ($0.94) EPS and FY2027 earnings at ($0.69) EPS.

Several other research analysts also recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price target on shares of Edesa Biotech in a research note on Monday, November 3rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Edesa Biotech in a research report on Monday. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $5.00.

Edesa Biotech Stock Down 2.0%

Shares of Edesa Biotech stock opened at $1.49 on Wednesday. The stock’s fifty day moving average is $1.93 and its two-hundred day moving average is $2.15. The company has a market capitalization of $12.42 million, a PE ratio of -1.10 and a beta of 0.08. Edesa Biotech has a 52 week low of $1.44 and a 52 week high of $4.49.

Edesa Biotech (NASDAQ:EDSA) last released its earnings results on Friday, December 12th. The company reported $0.53 EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.80. The business had revenue of $0.25 million for the quarter.

Institutional Investors Weigh In On Edesa Biotech

Large investors have recently modified their holdings of the business. Stonepine Capital Management LLC bought a new position in shares of Edesa Biotech during the first quarter valued at approximately $1,678,000. Velan Capital Investment Management LP purchased a new stake in Edesa Biotech during the first quarter worth $1,678,000. Nantahala Capital Management LLC purchased a new stake in Edesa Biotech during the first quarter worth $1,525,000. Finally, Susquehanna International Group LLP bought a new stake in Edesa Biotech during the 3rd quarter valued at $36,000. Institutional investors own 5.50% of the company’s stock.

About Edesa Biotech

Edesa Biotech, Inc, a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis.